Tuberculosis in times of COVID-19

Alexandra Jaye Zimmer 1,2, Joel Shyam Klinton 1,2,3 Charity Oga-Omenka 1,2, Petra Heitkamp 2,3, Carol Nawina Nyirenda 4, Jennifer Furin 5, Madhukar Pai 1,2

ABSTRACT
The COVID-19 pandemic has caused widespread disruptions to tuberculosis (TB) care and service delivery in 2020, setting back progress in the fight against TB by several years. As newer COVID-19 variants continue to devastate many low and middle-income countries in 2021, the extent of this setback is likely to increase. Despite these challenges, the TB community can draw on the comprehensive approaches used to manage COVID-19 to help restore progress and mitigate the impact of COVID-19 on TB. Our team developed the ‘Swiss Cheese Model for Ending TB’ to illustrate that it is only through multisectoral collaborations that address the personal, societal and health system layers of care that we will end TB. In this paper, we examine how COVID-19 has impacted the different layers of TB care presented in the model and explore how we can leverage some of the lessons and outcomes of the COVID-19 pandemic to strengthen the global TB response.

INTRODUCTION
Prior to COVID-19, tuberculosis (TB) was the leading infectious disease killer globally. In 2019 alone, there were approximately 10.0 million new TB infections and 1.5 million TB deaths globally. Over the past decades, efforts to curb the TB epidemic have gradually intensified. By the end of 2019, seventy-eight countries (including seven high-burden countries (HBC)) were on track to achieve the 2020 End TB goals of reducing TB incidence by 80% and TB mortality by 90%, compared with 2015 rates. However, the COVID-19 pandemic and lockdown measures have created a massive global setback towards achieving these goals as TB services were disrupted at every level of the healthcare system.

Impact of COVID-19 on TB services
According to the Global Fund’s snapshot report from 502 health facilities across Asia and Africa, TB referrals have fallen by 59% in the second and third quarters of 2020 compared with the same period in 2019. Data from the World Health Organization (WHO) in March 2021 showed that COVID-19-related disruptions have severely impacted over 84 countries with 1.4 million fewer people estimated to have received TB care in 2020, representing a 21% drop relative to 2019 (figure 1). In May 2020, the Stop TB Partnership published one of the earliest models on the impact of COVID-19 on TB, estimating a setback of at least 5–8 years in the fight against TB. More recently, a model by Hogan et al found that over the next 5 years TB deaths in high-burden settings could increase by up to 20%. These projections are a warning of what is to come unless a coordinated effort is implemented that addresses the layers of TB care.

During the second year of the pandemic, driven by newer, more transmissible variants (the Delta variant, in particular), the COVID-19 epicentres have shifted towards lower- and middle-income countries, many of which are struggling to manage second, or even third, waves of COVID-19. South Asia and South America have been hit particularly hard in 2021. By May, Latin America and the Caribbean surpassed 1 million COVID-19 deaths, the majority of which occurred in Brazil. India’s daily COVID-19 infections hit an all-time high with 414,188 cases recorded on 6 May 2021 (which is likely an underestimation), with an estimated excess death toll of 3–5 million during the pandemic, while neighbouring Bangladesh, Nepal, Myanmar, Sri Lanka and Indonesia experienced similar surges. We are also starting to see worrying increases in COVID-19 cases across the African continent, with South Africa, Uganda, South Africa, the Democratic Republic of Congo, Namibia and Angola reporting new surges. Many of these are also TB HBCs, and now have the added burden of dealing with a ‘syndemic’ of TB and COVID-19.

Because the devastation caused by the Delta variant in 2021 in HBCs was not accounted for in early 2020 projections and models, one may speculate that the impact of COVID-19 on TB disease and mortality rates may in fact be much worse than previously estimated. A recent review by McQuaid et al provides a detailed summary of studies that have quantified the country-level TB service disruptions among the 48 TB, TB-HIV and multidrug-resistant HBCs. The overall conclusion was that TB health services have decreased significantly in these settings due to COVID-19. In order to mitigate the impact of COVID-19 on TB, a comprehensive and coordinated approach to TB care and control that addresses the multiple layers of TB care is urgently needed.

COVID-19 shows the need for a comprehensive approach for disease control
Everyone is comfortable with the idea that COVID-19 requires multiple interventions, some personal (eg, masking, vaccinations), while others are societal (eg, social benefits, sick leave). The ‘Swiss Cheese Respiratory Pandemic Defense’ model created by Ian M Mackay outlines the multiple layers of these personal and shared responsibilities needed to prevent the spread of COVID-19.

This model was adapted by our team to represent the TB context as the ‘Swiss Cheese Model for
Ending TB’, outlining the layers of interventions needed to end TB (figure 2). The TB Swiss Cheese Model has three broad levels: societal, personal and person-centric healthcare system. Within each level, layers of interventions have gaps (‘holes’) that lead to negative TB outcomes, and it is only by addressing these multiple layers that we protect individuals from either TB infection or TB-related mortality. Previously, TB care has primarily focused on empowering healthcare workers, emphasising vertical diagnostics and treatment systems. TB care also prioritised the ‘simplistic’ over the comprehensive, attempting to address only one or two aspects of the disease (eg, only diagnosing and treating people with a positive smear or people with drug-sensitive TB).

Recently, more attention is being given towards strengthening person-centred care, as illustrated in the TB Swiss Cheese Model, and COVID-19 has further highlighted the importance of societal and personal factors. In this paper, we describe how COVID-19 has worn down some of the protective TB Swiss cheese layers, increasing the risk of poor outcomes for people with TB, while simultaneously creating opportunities to reinforce other layers by leveraging some of the technology and public health tools used to combat COVID-19.

**SOCIETAL**

**Tackle social determinants of health and inequities**

The social determinants of health that lead to TB infection and mortality overlap with those related to COVID-19 infection and mortality. Socioeconomic status, lack of political will to spend on health, physical environment and demographic factors are strong predictors of adverse health outcomes for both diseases.

It is estimated that between 88 and 93 million individuals were pushed into extreme poverty in 2020 because of the pandemic, a number that is increasing during 2021. Food insecurity and hunger are also rising. As of April 2021, approximately 111 million additional people situated in 35 low and middle-income countries were living without sufficient food compared with April 2020. Poverty and poor nutritional status are inextricably linked with poor TB outcomes. In India, it is estimated that a population-level reduction in body mass index due to COVID-19-related disruptions to food access is expected to cause a 13.8% increase in TB incidence among the poor. Shelter-in-place orders have confined many vulnerable individuals and families to their homes, increasing the social challenges of economic and food insecurity while simultaneously increasing the rates of household TB transmission. As more individuals are pushed into poverty and hunger because of the pandemic, it is inevitable that more people will become infected with, and die of, TB.

While TB has many upstream determinants of health, it is also in itself a determinant of health for other diseases, including COVID-19. A study from Western Cape, South Africa, found that both current and prior TB significantly increased the risk of COVID-19 mortality. Another study from Khayelitsha, South Africa, found that a positive COVID-19 test was associated with a higher risk of mortality among people with rifampicin-resistant (RR) TB (61% mortality in RR-TB individuals with COVID-19).

**Figure 1** Annual change in tuberculosis (TB) case notification among 84 countries reporting monthly or quarterly TB case notification data (2016–2020). Arrow represents the per cent change in TB notifications relative to the previous year. Data from the WHO.

**Figure 2** The Swiss Cheese Model for Ending TB (adapted for TB by Furin and Pai [13], with permission from Dr Ian Mackay). With input from Amrita Daftary, Petra Heitkamp, Joel Klinton, Emily MacLean, Lena Faust, Giorgia Sulis, Sophie Huddart and Anita Svadzian. POC, point of care; TB, tuberculosis.
Providing TB care without addressing underlying comorbidities and social determinants of TB is inadequate, particularly in the wake of the COVID-19 pandemic. Further, addressing the social determinants of TB and reducing TB incidence directly reduces COVID-19 mortality. The pandemic has amplified the urgent need to develop effective interventions that address the health equity gap underlying barriers to universal health coverage in order to simultaneously control the spread and mitigate the impact of both COVID-19 and TB.

**Vaccines**

Vaccination is a key societal prevention strategy both for COVID-19 and TB. As of 1 June 2021, there were 287 candidate vaccines in development for COVID-19. Among these, 185 were in preclinical development and 102 in clinical development, 14 of which are approved. Comparatively, there are only 18 TB candidate vaccines in development for adolescents and adults as of October 2020, none of which have moved beyond phase III of clinical trials. The only TB vaccine licensed for use is the BCG vaccine; a childhood vaccine developed in 1921 that offers variable protection with waning efficacy. The M72/AS01E TB vaccine candidate is one of the most advanced TB vaccines for adults, having just completed phase Ib trials in early 2020, and yet, the projected time to product availability is 2028. This contrast is partly due to differences in political will and funding: between 2005 and 2019 TB vaccine research received US$1.4 billion globally while the vaccine pillar of the CT) Accelerator for COVID-19 received US$9.5 billion globally within just over 1 year (as of 1 June 2021).

While progress in vaccine development is typically hindered, the monumental advancements in COVID-19 vaccine development and technology, including the new benchmark set by the remarkable speed of development, present future opportunities for TB vaccine development. Additionally, there is hope that the technology behind the novel mRNA vaccines could be leveraged to develop an effective TB vaccine. Finally, the momentum behind COVID-19 vaccine development has given rise to promising collaborative initiatives for TB vaccine development, including the global road map for TB vaccine development launched by the European and Developing Countries Clinical Trials Partnership and the Amsterdam Institute for Global Health and Development.

Until a more effective TB vaccine is available, it is essential that BCG vaccination levels are maintained. However, the United Nations estimates that 23 million children missed out on basic, routine childhood vaccines in 2020. Data from Pakistan and India also reveal sharp declines in the number of BCG vaccinations administered during the lockdown. Reasons for decreased coverage are linked to decreased access to health facilities due to lockdown measures as well as vaccine supply chain challenges. Maintaining supplies of BCG for infants during COVID-19 is essential to prevent severe forms of paediatric TB.

**Public education, community engagement and stigma reduction**

Information, health education, communication, and addressing knowledge, attitudes and behaviours are essential disease prevention and control strategies. In TB control, these are often used in conjunction with active case finding and to promote treatment adherence. COVID-19 has brought many outreach campaigns and community drives to a halt. However, some programmes integrated TB and COVID-19 public awareness through public announcements, media campaigns and educational pamphlets that aimed to educate people about both diseases. For example, Mercy Corps in Pakistan helped disseminate information about TB and COVID-19 through mosque announcements and FHI 360 Philippines partnered with a media company to build social media campaigns. The adoption of such community-based educational models strengthens the person-centred approach to TB prevention. COVID-19 has also spearheaded the development of more advanced digital educational tools. For example, COVID-19 HealthAlert by Prakell disseminates accurate and up-to-date COVID-19 information at a population level via WhatsApp, and was able to reach more than 6 million individuals within the first 7 weeks of deployment.

Nevertheless, the rapid dissemination of misinformation on digital communication platforms and social media can be a threat to public health. For TB control, misinformation can result in delayed care seeking, increased transmission and poor health outcomes. Because of the overlapping symptoms between COVID-19 and TB, stigma and misinformation on TB have increased significantly. Results from a global community-based survey found that 56% of people with TB from Kenya (n=159) reported feelings of shame because of the overlapping symptoms with COVID-19. In order to minimise TB-related stigma and ensure individuals make informed health decisions, it is essential that information on TB continues to be delivered to at-risk communities.

Another important aspect of community engagement to consider is contact tracing. Contact tracing is a core strategy used to curb both TB and COVID-19 transmission, particularly in regions where the COVID-19 epidemic curve is flattened or declining. Effective contact tracing may help address stigma, community trust and engagement, and use of operational guidelines for both TB and COVID-19. Many of the COVID-19 contact tracing initiatives have drawn on TB programme staff expertise, though sometimes at the detriment to TB prevention and control efforts. A report published by the Centers for Disease Control and Prevention’s (CDC) Division of Tuberculosis Elimination found that among 50 TB programmes in the USA, 60% experienced a partial or high impact on TB staffing capacity for outreach (including contact investigations). Contact tracing initiatives are some of the more labour and resource-intensive strategies for both TB and COVID-19. Unless proper resource allocation guidelines are in place that simultaneously address the needs of both TB and COVID-19, one disease will become deprioritised, as is currently the case for TB. In order to address the growing backlog of undiagnosed TB cases, an integrated, dual TB and COVID-19 contact tracing approach is needed to maximise the use of staff and resources.

**PERSONAL**

**Early care seeking for TB symptoms or if exposed**

During the first months of the pandemic, TB notifications decreased sharply in HBCs. Restriction in movement, fear of contracting or being misdiagnosed with COVID-19, and stigma all impacted care seeking. The global survey found that 50% of people with TB in Kenya (n=159) reported having trouble accessing TB care due to restricted access to public transportation (cost and availability of transport). From the same survey, 62% of people with TB from India (n=58) reported that they did not want to visit their regular facility out of fear of contracting COVID-19. One study from an infectious disease referral hospital in Italy found that between March and August
2020, the median delay to seeking a TB diagnosis increased by 30 days compared with the same period in 2019. This delay in care seeking has contributed to a growing pool of missed people, leading to surges in community-based TB transmission, more severe forms of TB, and TB mortality. Innovations include over-the-counter antigen detection tests, face masks that detect SARS-CoV-2 RNA in aerosols and mouth/saliva swabs for facilitated sample collection. Innovators must work towards integrating these new tools for improved TB screening and care.

PERSON-CENTRIC HEALTHCARE SYSTEM

The rapid innovation in tools driven by the COVID-19 pandemic may present opportunities for improved community-based TB screening, including testing closer to homes. Such tools include over-the-counter antigen detection tests, face masks that detect SARS-CoV-2 RNA in aerosols and mouth/saliva swabs for facilitated sample collection.

Screening for infection and disease

Many community-based screening, contact tracing, and active case finding initiatives were hindered during COVID-19, resulting in a reduction or discontinuation of TB screening efforts. In Nigeria, the Wellness on Wheels campaign, which uses mobile diagnostic units to screen patients with digital X-ray machines, experienced a 67% decrease in patients screened between 8 and 29 March 2020. A rapid assessment of intermediary agencies involved in TB care also reported screening and outreach disruptions across seven HBCs. Shelter-at-home orders have made screening more challenging as individuals are not able to access health facilities. Also, people with TB who are confined to their homes increase the risk of household transmission, particularly among vulnerable populations living in crowded households. As community and household-based screening initiatives are essential to promote community screening initiatives that follow person-centred models.

PERSON-CENTRIC HEALTHCARE SYSTEM

TB preventive therapy

As many individuals with TB are confined at home, it is essential that household contacts receive effective preventive therapies. According to McQuaid et al, Brazil, Kenya, the Philippines, Russia, South Africa, Sierra Leone and Zambiam reported a 30%–70% decrease in preventive therapy enrollment. One model published in November 2020 estimated that the proportion of people living with HIV receiving isoniazid preventive therapy (IPT) in Kenya could drop to 10% due to disruptions caused by COVID-19 lockdowns.

Despite this, COVID-19 has successfully altered stigmatised perceptions surrounding the administration of anti-TB preventive therapy in some settings. A programme in Khayelitsha, South Africa that provides TB preventive therapy to children and adolescents exposed to RR-TB in households found that ‘there is increased acceptance of tuberculosis preventive therapy compared with before the pandemic, possibly due to changed risk perceptions’. Thus, while the pandemic may currently affect the ability of health providers to administer IPT, changes in risk perception brought about by the pandemic may help improve IPT uptake in the long term.

Early detection of TB disease using point-of-care and molecular diagnostics

From a health systems perspective, the lack of diagnostic capacity to support simultaneous testing for both COVID-19 and TB presented a major barrier to adequate TB control measures. With the release of the GeneXpert Xpress SARS-CoV-2 cartridge by Cepheid, global networks of GeneXpert machines normally used to test TB were disrupted. Forty-three countries, including 13 HBCs, reported using GeneXpert for COVID-19 testing instead of TB testing.

Instead of reallocating diagnostic resources from TB towards COVID-19, the WHO recommends multidisease testing strategies, as is already being implemented in India. The overlapping epidemiology and clinical characteristics of these diseases is a call for healthcare providers and researchers to move away from vertical disease-specific approaches, which has long impeded TB control, towards comprehensive and integrated methods. Similar to screening tools, COVID-19 has spearheaded the development of novel diagnostics. Promising tools include point-of-care chest radiology and cough detection technologies that can potentially be used to differentiate COVID-19 from TB and other respiratory ailments in low-resource settings.

Quality of care, including safe and effective regimens

Even before COVID-19, TB quality of care was considered suboptimal; however, the pandemic has only worsened the quality of care people with TB receive. Failure to provide treatment in a timely fashion is a TB-related human rights violation. Therefore, the appropriateness of rigid adherence support strategies, such as facility-based directly observed therapy (DOT), has come under increased scrutiny during the pandemic. In many settings, facility-based DOT became impossible during COVID-19—patients could not access the health centre or were not allowed in, resulting in many people missing therapy.
overcome the barriers created by facility-based DOT, there has been a shift towards strengthening community-based TB treatment services to ensure patients get the medicine in a timely fashion. Other strategies include multimonth dispensing and home delivery of treatment. In the Philippines, the Department of Health issued a memorandum urging TB services to provide a 1-month supply of anti-TB medication instead of going to the facility for their daily dose. This was issued after noting a near 10-fold decrease in patients receiving their treatment during the first quarter of 2020 compared with the same time period in 2019. While home-based options, including delivery of medications to patients’ homes, have made treatment more accessible, counselling and treatment literacy support were often missing. The increased acceptance and uptake of video DOT (vDOT) and other telemedicine options has helped overcome the barriers to non-medical support systems; however, this may only be an option in locations that have sufficient data/internet coverage. Therefore, community-based care services must remain available in addition to vDOT strategies in order to provide more flexible treatment options during and beyond the COVID-19 pandemic.

**Patient support and managing comorbidities**

While anti-TB therapy is needed to manage disease progression, it is not sufficient to prevent mortality. Non-medical support that places the person at the centre of care is essential for successful outcomes. This includes nutritional, financial, counselling, and psychosocial support. As previously discussed, many of these support systems fell apart during COVID-19. It is important for health systems to adapt their health delivery strategies to include non-medical support, particularly for vulnerable populations burdened by social determinants and comorbidities that increases their risk of TB and/or COVID-19. A recent survey, which collected responses from 567 people with TB across 64 countries, found that 31% of respondents reported that non-medical support ‘was much harder or impossible to access’ during COVID-19. It is also important to recognise that not all people with TB require the same amount of care, as individuals with multidrug resistance or other comorbidities may require additional support. Comorbidities such as HIV and diabetes are particularly important to address as they increase the chance of mortality among people with TB. A 2020 WHO rapid assessment of COVID-19 on non-communicable diseases found that 49% of the 163 ministries surveyed reported partial or complete disruption to services for diabetes and diabetes-related complications. COVID-19 also disrupted HIV services, including screening and antiretroviral therapy delivery. These disruptions have made comprehensive care even more inaccessible for people with TB living with comorbidities. That said, the immense efforts that have gone into characterising COVID-19 mortality risk factors have highlighted the importance of managing comorbidities, such as diabetes and HIV, to reduce deaths. In order to make progress towards achieving TB elimination goals, we must work towards integrated TB care programmes that address the needs of individuals living with comorbidities, including options that integrate remote and home-based care.

**TB infection control**

COVID-19 has promoted capacity-building efforts for IPC within healthcare systems (eg, use of masks and personal protective equipment (PPE)). Historically, adherence to IPC guidelines for respiratory diseases has been poor. As IPC guidelines for COVID-19 infection control are reinforced and adopted, this will facilitate the control and prevention of TB within healthcare facilities.

This awareness and capacity building is particularly important for primary care facilities, which play an important role for early TB detection and care, both before and during COVID-19. In Pakistan, many tertiary and secondary care hospitals closed their outpatient facilities to minimise COVID-19 transmission. As a result, many patients with TB were redirected to primary healthcare centres. An assessment of these primary facilities revealed low adherence to IPC measures in addition to poor supply chain management of drugs and consumables. In response, Pakistan’s National TB Program trained healthcare professionals at primary facilities on proper use of PPE, supplemented by ‘comprehensive educational modules on infection control which were prepared and delivered through online training to field staff’. Thus, while COVID-19 has put enormous strains on healthcare systems globally, it also raised awareness of important infectious respiratory disease IPC measures in healthcare settings. Greater use of masks by patients, PPE by providers, and engineering controls such as ultraviolet light fixtures and better ventilation will greatly help nosocomial transmission of both COVID-19 and TB.

**CONCLUSION**

The severe disruptions of TB care and services caused by COVID-19 have set back progress towards achieving global TB targets, including the 2018–2022 United Nations High-Level Meeting targets on TB treatment and prevention as well as the End TB objective of ending the TB epidemic by 2035. In order to restore progress towards TB elimination, a more refined and multifaceted approach to managing TB is needed. The Swiss Cheese Model for Ending TB highlights that single layers of protection are insufficient to end TB, and instead stresses the need for a holistic approach to TB care that calls for the strengthening of societal, personal and health system layers simultaneously. While these layers are essential to TB control, other cross-cutting and programmatic considerations must be re-evaluated in order to adapt to the current global situation under COVID-19. Such actions include reaffirming political support, scaling up TB investments and improving the timeliness and quality of TB data reporting. There is no magic bullet to managing TB. Public health responses are not single interventions but closely intertwined with societal beliefs and actions.

**Correction notice** This article has been corrected since it first published. Figure 1 formatting has been corrected and reference 2 has been corrected.

**Twitter** Alexandra Jaye Zimmer @alexjzimmer, Joel Shyam Klinton @drjoelklinton, Petra Heitkamp @PetraHeitkamp and Madhukar Pai @paimadhu

**Acknowledgements** The authors used publicly available data (already reported in the media) for displaying the impact of COVID-19 on tuberculosis services. We thank Amrita Daftary, Emily MacLean, Lena Faust, Giorgia Sulis, Sophie Huddart and Anita Svazdian for their input on the ‘Swiss Cheese Model for Ending TB’.

**Contributors** JSSK, PH, JF and MP developed the Swiss Cheese Model for Ending TB used to structure this manuscript. AJZ, JSSK, CO-O, PH and MP conceived the manuscript. AJZ wrote the original manuscript with input from all authors.

**Funding** This work was supported, in whole or in part, by the Bill & Melinda Gates Foundation.

**Competing interests** MP serves as an advisor to the Bill & Melinda Gates Foundation, WHO Stop TB Partnership and Foundation for Innovative New Diagnostics.

**Patient consent for publication** Not required.

**Provenance and peer review** Commissioned; externally peer reviewed.

**Data availability statement** No data are available. Data sharing is not applicable to this article as no new data were created or analysed in this study.
Open access  This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

ORCID iDs
Alexandra Jaye Zimmer http://orcid.org/0000-0002-6047-0923
Joel Shyma Clinton http://orcid.org/0000-0003-4850-3961
Madhukar Pai http://orcid.org/0000-0003-3667-4536

REFERENCES


